Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Breast Cancer STAT Panel

Invitae has launched the Breast Cancer STAT Panel, a rapid turnaround gene panel that includes seven genes with surgical and therapeutic relevance: BRCA1, BRCA2, CDH1, PALB2, PTEN, SK11, and TP53. Mutations in these genes may influence patient and physician decisions on mastectomy versus lumpectomy, and whether to prophylactically remove the ovaries and fallopian tubes. Results of the panel can also help guide choice of chemotherapy. Turnaround time is eight to 12 calendar days. Price per indication is the same as Invitae's other tests — $950 for payors and institutions that are in contract with the company, $1,500 for third party payors that are out of network, and $475 for patients without insurance or who do not meet their insurance's criteria for coverage.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.